The second-highest correlation was found between SLC1A5 expression and CD86, a marker gene of tumor-associated macrophages with the ability to capture PD1-targeting antibodies on its surface and consequently limiting immunotherapeutic efficacy (59). This evidence concerns the gene SLC1A5 and neoplasm.